Quest Diagnostics Net Profit Margin 2012-2025 | DGX
Current and historical net profit margin for Quest Diagnostics (DGX) from 2012 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Quest Diagnostics net profit margin for the three months ending September 30, 2025 was .
| Quest Diagnostics Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2025-09-30 | $10.85B | $0.96B | 8.88% |
| 2025-06-30 | $10.52B | $0.95B | 8.98% |
| 2025-03-31 | $10.16B | $0.89B | 8.78% |
| 2024-12-31 | $9.87B | $0.87B | 8.77% |
| 2024-09-30 | $9.54B | $0.84B | 8.80% |
| 2024-06-30 | $9.35B | $0.84B | 8.95% |
| 2024-03-31 | $9.29B | $0.84B | 9.07% |
| 2023-12-31 | $9.25B | $0.85B | 9.19% |
| 2023-09-30 | $9.30B | $0.76B | 8.15% |
| 2023-06-30 | $9.49B | $0.79B | 8.34% |
| 2023-03-31 | $9.60B | $0.79B | 8.22% |
| 2022-12-31 | $9.88B | $0.94B | 9.53% |
| 2022-09-30 | $10.29B | $1.23B | 11.92% |
| 2022-06-30 | $10.58B | $1.48B | 13.95% |
| 2022-03-31 | $10.68B | $1.87B | 17.55% |
| 2021-12-31 | $10.79B | $1.99B | 18.43% |
| 2021-09-30 | $11.05B | $2.18B | 19.72% |
| 2021-06-30 | $11.06B | $2.24B | 20.27% |
| 2021-03-31 | $10.34B | $1.80B | 17.37% |
| 2020-12-31 | $9.44B | $1.43B | 15.10% |
| 2020-09-30 | $8.36B | $1.11B | 13.22% |
| 2020-06-30 | $7.53B | $0.75B | 9.99% |
| 2020-03-31 | $7.66B | $0.79B | 10.36% |
| 2019-12-31 | $7.73B | $0.86B | 11.11% |
| 2019-09-30 | $7.64B | $0.73B | 9.58% |
| 2019-06-30 | $7.57B | $0.73B | 9.64% |
| 2019-03-31 | $7.54B | $0.72B | 9.59% |
| 2018-12-31 | $7.53B | $0.74B | 9.77% |
| 2018-09-30 | $7.56B | $0.86B | 11.42% |
| 2018-06-30 | $7.52B | $0.81B | 10.78% |
| 2018-03-31 | $7.47B | $0.79B | 10.51% |
| 2017-12-31 | $7.40B | $0.77B | 10.43% |
| 2017-09-30 | $7.10B | $0.67B | 9.44% |
| 2017-06-30 | $7.13B | $0.70B | 9.84% |
| 2017-03-31 | $7.17B | $0.70B | 9.81% |
| 2016-12-31 | $7.21B | $0.64B | 8.90% |
| 2016-09-30 | $7.50B | $0.68B | 9.00% |
| 2016-06-30 | $7.50B | $0.83B | 11.00% |
| 2016-03-31 | $7.52B | $0.75B | 9.95% |
| 2015-12-31 | $7.49B | $0.71B | 9.42% |
| 2015-09-30 | $7.53B | $0.71B | 9.45% |
| 2015-06-30 | $7.55B | $0.50B | 6.60% |
| 2015-03-31 | $7.53B | $0.51B | 6.81% |
| 2014-12-31 | $7.44B | $0.56B | 7.48% |
| 2014-09-30 | $7.31B | $0.51B | 6.96% |
| 2014-06-30 | $7.19B | $0.79B | 10.91% |
| 2014-03-31 | $7.11B | $0.82B | 11.50% |
| 2013-12-31 | $7.15B | $0.85B | 11.88% |
| 2013-09-30 | $7.16B | $0.76B | 10.64% |
| 2013-06-30 | $7.20B | $0.52B | 7.22% |
| 2013-03-31 | $7.26B | $0.53B | 7.34% |
| 2012-12-31 | $7.38B | $0.56B | 7.53% |
| 2012-09-30 | $7.37B | $0.69B | 9.36% |
| 2012-06-30 | $7.45B | $0.70B | 9.38% |
| 2012-03-31 | $7.48B | $0.68B | 9.15% |
| 2011-12-31 | $7.39B | $0.47B | 6.37% |
| 2011-09-30 | $7.35B | $0.45B | 6.08% |
| 2011-06-30 | $7.31B | $0.47B | 6.48% |
| 2011-03-31 | $7.28B | $0.51B | 6.94% |
| 2010-12-31 | $7.26B | $0.72B | 9.93% |
| 2010-09-30 | $7.39B | $0.74B | 9.97% |
| 2010-06-30 | $7.43B | $0.73B | 9.84% |
| 2010-03-31 | $7.45B | $0.72B | 9.71% |
| 2009-12-31 | $7.46B | $0.73B | 9.78% |
| 2009-09-30 | $7.41B | $0.72B | 9.68% |
| 2009-06-30 | $7.34B | $0.64B | 8.67% |
| 2009-03-31 | $7.27B | $0.61B | 8.37% |
| 2008-12-31 | $7.25B | $0.58B | 8.03% |
| 2008-09-30 | $7.22B | $0.41B | 5.64% |
| 2008-06-30 | $7.16B | $0.39B | 5.50% |
| 2008-03-31 | $6.96B | $0.37B | 5.37% |
| 2007-12-31 | $6.70B | $0.34B | 5.07% |
| 2007-09-30 | $6.48B | $0.49B | 7.62% |
| 2007-06-30 | $6.30B | $0.56B | 8.84% |
| 2007-03-31 | $6.24B | $0.55B | 8.78% |
| 2006-12-31 | $6.27B | $0.59B | 9.37% |
| 2006-09-30 | $6.12B | $0.57B | 9.28% |
| 2006-06-30 | $5.90B | $0.54B | 9.19% |
| 2006-03-31 | $5.69B | $0.56B | 9.82% |
| 2005-12-31 | $5.46B | $0.55B | 10.01% |
| 2005-09-30 | $5.28B | $0.54B | 10.26% |
| 2005-06-30 | $5.21B | $0.54B | 10.31% |
| 2005-03-31 | $5.13B | $0.52B | 10.04% |
| 2004-12-31 | $5.07B | $0.50B | 9.85% |
| 2004-09-30 | $5.05B | $0.48B | 9.53% |
| 2004-06-30 | $4.98B | $0.47B | 9.46% |
| 2004-03-31 | $4.90B | $0.46B | 9.47% |
| 2003-12-31 | $4.74B | $0.44B | 9.20% |
| 2003-09-30 | $4.57B | $0.41B | 8.98% |
| 2003-06-30 | $4.41B | $0.38B | 8.56% |
| 2003-03-31 | $4.26B | $0.34B | 8.08% |
| 2002-12-31 | $4.11B | $0.32B | 7.86% |
| 2002-09-30 | $3.99B | $0.29B | 7.33% |
| 2002-06-30 | $3.83B | $0.26B | 6.66% |
| 2002-03-31 | $3.69B | $0.19B | 5.23% |
| 2001-12-31 | $3.63B | $0.16B | 4.47% |
| 2001-09-30 | $3.55B | $0.14B | 3.83% |
| 2001-06-30 | $3.50B | $0.12B | 3.28% |
| 2001-03-31 | $3.45B | $0.12B | 3.48% |
| 2000-12-31 | $3.42B | $0.10B | 2.98% |
| 2000-09-30 | $3.40B | $0.06B | 1.82% |
| 2000-06-30 | $3.16B | $0.02B | 0.76% |
| 2000-03-31 | $2.68B | $0.01B | 0.26% |
| 1999-12-31 | $2.21B | $0.00B | -0.18% |
| 1999-09-30 | $1.75B | $0.02B | 0.91% |
| 1999-06-30 | $1.50B | $0.03B | 2.07% |
| 1999-03-31 | $1.47B | $0.03B | 1.83% |
| 1998-12-31 | $1.46B | $0.03B | 1.85% |
| 1998-09-30 | $1.46B | $-0.02B | -1.03% |
| 1998-06-30 | $1.47B | $-0.02B | -1.22% |
| 1998-03-31 | $1.51B | $-0.02B | -1.26% |
| 1997-12-31 | $1.53B | $-0.02B | -1.44% |
| 1997-09-30 | $1.55B | $0.01B | 0.90% |
| 1997-06-30 | $1.58B | $-0.11B | -6.84% |
| 1997-03-31 | $1.60B | $-0.15B | -9.61% |
| 1996-12-31 | $1.62B | $-0.61B | -37.93% |
| 1996-09-30 | $1.62B | $-0.63B | -38.62% |
| 1996-06-30 | $1.62B | $-0.55B | -33.79% |
| 1996-03-31 | $1.61B | $-0.51B | -31.74% |
| 1995-12-31 | $1.63B | $-0.05B | -3.25% |
| 1995-09-30 | $1.64B | $-0.02B | -1.34% |
| 1995-06-30 | $1.65B | $-0.02B | -1.21% |
| 1995-03-31 | $1.65B | $0.01B | 0.48% |
| 1994-12-31 | $1.63B | $0.03B | 1.71% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $19.405B | $9.872B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health (ELAN) | United States | $11.661B | 24.45 |
| Encompass Health (EHC) | United States | $10.356B | 19.91 |
| DaVita (DVA) | United States | $7.868B | 11.49 |
| Chemed (CHE) | United States | $6.295B | 22.11 |
| RadNet (RDNT) | United States | $6.033B | 205.79 |
| Option Care Health (OPCH) | United States | $5.048B | 21.49 |
| LifeStance Health (LFST) | United States | $2.879B | 0.00 |
| Addus HomeCare (ADUS) | United States | $2.028B | 20.94 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.795B | 22.60 |
| Astrana Health (ASTH) | United States | $1.600B | 149.63 |
| U.S Physical Therapy (USPH) | United States | $1.277B | 32.29 |
| Pennant (PNTG) | United States | $0.973B | 32.33 |
| Daxor (DXR) | United States | $0.069B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.054B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |